As ordered reported by the House Committee on Oversight and Accountability on May 15, 2024
By Fiscal Year, Millions of Dollars
2024
2024-2029
2024-2034
Direct Spending (Outlays)
*
*
*
Revenues
0
0
0
Increase or Decrease (-) in the Deficit
*
*
*
Spending Subject to Appropriation (Outlays)
*
*
not estimated
Increases net direct spending in any of the four consecutive 10-year periods beginning in 2035?
*
Statutory pay-as-you-go procedures apply?
Yes
Mandate Effects
Increases on-budget deficits in any of the four consecutive 10-year periods beginning in 2035?
*
Contains intergovernmental mandate?
No
Contains private-sector mandate?
No
* = between zero and $500,000.
Summary
H.R. 8333 would prohibit federal agencies from awarding contracts, grants, or loans to biotechnology companies owned by foreign adversaries. The ban would immediately apply to five companies: BGI Group, MGI, Complete Genomics, WuXi AppTec, and WuXi Biologics. The bill also would require the Administration to review and modify the list of prohibited companies on an annual basis. H.R. 8333 would permit federal agencies to waive the ban for a maximum of 545 days on a case-by-case basis.
